Men in the United States have a 1 in 6 chance of developing prostate cancer in their lifetime. It is, therefore, likely that we all know somebody who has been touched by the disease. To put this data in perspective, approximately 1 in 8 women in the United States will develop breast cancer.
Bone metastases are seen in 90% of men with castration-resistant prostate cancer (CRPC). Patients may experience pain at the site of the metastases, a pain that gradually increases in intensity over time.
Sally Church on Pharma Strategy Blog has written about the experience of her father who died from Prostate Cancer, and the pain he suffered from untreated bone mets.
In a podcast from AUA 2011 Sally interviewed Dr Neil Shore on Pharma Strategy Blog and asked him why treatment of bone metastases was important, and his views on the risks/benefits associated with denosumab. It is well worth listening to.
Dr Shore will be presenting further data on denosumab and skeletal related events (SREs) at ASCO (Abstract #4533)